Successful Treatment of ANCA-Negative Wegener's Granulomatosis with Rituximab by Khan, Afsha et al.
Hindawi Publishing Corporation
International Journal of Rheumatology
Volume 2010, Article ID 846063, 2 pages
doi:10.1155/2010/846063
Case Report
SuccessfulTreatment of ANCA-Negative Wegener’s
Granulomatosiswith Rituximab
Afsha Khan, CatherineA. Lawson, Mark A. Quinn,Amanda H. Isdale, andMichael J. Green
Department of Rheumatology, York Hospital, Wigginton Road, York YO31 8HE, UK
Correspondence should be addressed to Michael J. Green, michael.green@york.nhs.uk
Received 25 April 2010; Revised 9 July 2010; Accepted 4 October 2010
Academic Editor: Ronald van Vollenhoven
Copyright © 2010 Afsha Khan et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Wegener’s Granulomatosis (WG) is a systemic vasculitis typically associated with antineutrophil cytoplasmic antibodies (ANCAs).
A small proportion of patients are ANCA negative, however, and this is more commonly found in individuals with disease limited
to the ears, nose, throat, and lungs, who do not have renal involvement. Rituximab is a monoclonal anti-CD20 antibody that has
been demonstrated to be eﬀective in the treatment of autoantibody-associated rheumatic diseases, including systemic WG. We
report the case of a patient with ANCA-negative WG who responded well to rituximab, illustrating that even in the absence of
detectable autoantibodies, B-cell depletion can be eﬀective.
1.Introduction
Up to 40% of patients with WG whose disease is limited to
ear, nose, throat (ENT), and lung manifestations are ANCA-
negative[1].Theroleofrituximabinthetreatmentoflimited
WG or ANCA-negative disease remains uncertain. We report
a case of a 21-year-old female with ANCA-negative WG
limited to ENT and lung involvement, who responded well
to rituximab with resolution of symptoms, normalisation of
inﬂammatory markers, and reduction of steroid therapy.
2.Case
A 20-year-old woman presented with a ﬁve-week history of
otalgia,eardischarge,anddeafness.Therewerenoadditional
systemic symptoms or signs. Audiometry showed bilateral
conductive hearing loss. She initially received antibiotics;
however due to severe otalgia, she had bilateral myringo-
tomies with grommet insertion without improvement. CT
and MRI revealed ﬂuid in the middle ear clefts and mastoid
cells bilaterally. Blood tests showed a C-reactive protein
(CRP) of 50mg/l, normal full blood count, renal and liver
functiontests,andanegativeANCA.Urinalysiswasnegative.
Oralprednisolone 60mgdailyresultedinsomesymptomatic
improvement. Seven weeks later, she developed a left lower
motor facial nerve palsy and reduced sensation in the middle
third of her face. Repeat MRI showed bilateral middle ear
inﬂammation but no additional intracranial abnormalities.
Further oral steroids again improved her symptoms. Nasal
and middle ear biopsies revealed evidence of a necrotising
inﬂammatory process, but no features of infection.
Further oral prednisolone improved the clinical symp-
toms with some subjective improvement in the facial
weakness and general well-being, and reduction in CRP.
Reducing steroids to 20mg resulted in deterioration of
symptoms, with increasing facial and ear pain plus a rise
in CRP. With this further deterioration despite corticos-
teroids, a decision was taken to escalate therapy and she
received cyclophosphamide with methylprednisolone plus
cotrimoxazole, with slow improvement noted in her left ear
hearing, clinical symptoms, and CRP. After three pulses,
aC Ts c a no fh e rl u n g sw a sr e q u e s t e dt oi n v e s t i g a t ea
persistent cough. Despite normal repeat chest radiographs,
cavitating lung lesions consistent with a diagnosis of WG
were demonstrated. Other possible diﬀerential diagnoses
including infections such as tuberculosis or Staphylococcus
aureus abscesses were considered less likely due to the clinical
and biochemical improvement with immunosupppression.
She also developed a saddle nose deformity at this time.
Relapsing polychondritis was thought to be unlikely given2 International Journal of Rheumatology
the pulmonary manifestations and the absence of external
ear cartilage involvement. Histology had not shown atypical
lymphocytes or histiocytes and so was not suggestive of
midline granulomatosis.
Followingsixpulsesofcyclophosphamide,shedeveloped
stridor, and a ﬂow volume loop was in keeping with a
subglottic tracheal stenosis. She required multiple tracheal
dilatations plus local steroid injections which brought
temporary relief for approximately six to eight weeks at
a time. After a further three pulses of cyclophosphamide,
she remained well with no symptoms of active disease
and a normal CRP. However, seven weeks after ﬁnishing
cyclophosphamide, she developed pain over the right mas-
toid and maxillary sinus, shortness of breath, recurrent
tracheal stenosis, increasing saddle nose deformity, and a rise
in CRP to 26mg/l. Despite her ANCA negativity, we felt that
rituximab was a reasonable therapeutic option. She received
two 1g doses of rituximab a fortnight apart, leading to a
marked improvement in mastoid, ear and nose pain, and a
fall in CRP within two months to normal levels. She was
subsequently commenced on mycophenolate although was
not initially able to take this regularly due to side eﬀects.
A reduction in oral steroid dose was possible. She has been
retreated empirically with rituximab on two occasions with
an average of seven months between infusions. She has
since felt well enough to return to her university studies.




We feel that this case oﬀers a number of learning points.
Firstly, patients presenting with upper respiratory tract
symptoms, bilateral middle ear symptoms, and cranial
neuropathies which cannot be explained by the eﬀects of
infection should have WG high on the list of diﬀerential
diagnoses. Secondly, this case illustrates response to B-
cell depletion in WG with predominant ENT symptoms,
cavitating lung lesions and cranial neuropathies where there
was no detectable antibody. It is logical to hypothesise
that elimination of B cells using rituximab might have a
favourable eﬀect on ANCA-associated WG by removing the
cells responsible for ANCA production [2–6]. However, the
mechanism by which B-cell depletion may act in ANCA-
negative cases is less clear. It may be that in these cases, B-
cells contribute to disease via additional roles such as antigen
presentation or interactions with T cells. Alternatively, high
aﬃnity ANCA may be strongly tissue bound resulting in
progressive severe disease. Finally, as has been reported
previously [7], rituximab was not helpful in preventing
the progression of all the disease-speciﬁc pathology and
subglottic stenosis continued to be a problem in this case.
Our patient has improved with operative intervention.
Limited WG, with clinical ﬁndings isolated to the upper
respiratory tract or the lungs, occurs in approximately one
quarter of cases. Although many of these patients (up to
80%) may subsequently develop glomerulonephritis, there
areincompletelyunderstoodphenotypicdiﬀerencesbetween
subtypesofWG[8].Patientswithlimiteddiseaseareyounger
at disease onset and likely to be female. They have longer dis-
ease duration on average than patients with systemic disease
and a greater likelihood of recurring disease. Patients with
limited disease also have a higher prevalence of destructive
upper respiratory disease as saddle nose deformity and are
less likely to be ANCA positive.
4. Conclusion
Our case illustrates that in ANCA-negative WG which
relapses at an early stage following conventional cyclophos-
phamide, there is a role for B-cell depletion despite the lack
of a detectable autoantibody target. In such cases, rituximab
may be an eﬀective therapeutic option.
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